Predictors of the clinical effects of pirfenidone on idiopathic ：吡非尼酮对特发性的临床疗效的预测.ppt

* Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis Toru Arai, Yoshikazu Inoue, Yumiko Sasaki, Kazunobu Tachibana, Keiko Nakao, Chikatoshi Sugimoto, Tomohisa Okuma, Masanori Akira, Masanori Kitaichi and Seiji Hayashi Respiratory Investigation Volume 52, Issue 2, Pages 136-143 (March 2014) DOI: 10.1016/j.resinv.2013.09.002 Copyright ? 2014 The Japanese Respiratory Society Terms and Conditions Fig. 1 Source: Respiratory Investigation 2014; 52:136-143 (DOI:10.1016/j.resinv.2013.09.002 ) Copyright ? 2014 The Japanese Respiratory Society Terms and Conditions Fig. 2 Source: Respiratory Investigation 2014; 52:136-143 (DOI:10.1016/j.resinv.2013.09.002 ) Copyright ? 2014 The Japanese Respiratory Society Terms and Conditions A change in vital capacity (VC; L/year) was compared with the Wilcoxon signed-rank test between 3 and 12 months before and 3 and 6 months after pirfenidone initiation with (A) severity grade I/II (n=10) and (B) severity grade III/IV (n=11). In severity grade I/II patients, the change in VC significantly decreased after pirfenidone initiation (p=0.0039) (A). However, the change in VC did not significantly decline in severity grade III/IV patients (p=0.1748) (B). The change in VC before pirfenidone administration in severity grade I/II patients was significantly smaller than that of severity grade III/IV patients with Wilcoxon rank-sum test (p=0.0290). Kaplan–Meier plots of anorexia/nausea-free time in IPF patients administered pirfenidone and acid-secretion inhibitors (solid line) or pirfenidone alone (dotted line). The median anorexia/nausea-free time from pirfenidone initiation to the onset of anorexia/nausea in patients with ≥grade 2 was significantly shorter in cases with no acid-secretion inhibitors (34 days) than in cases with acid-secretion inhibitors (324 days), as determined by log-rank test (p=0.0211). Cases that continued pirfenidone treatment and then stopped because of other adverse events, other than anorexia,